Trending News on Targeted Oncology, Week of September 18, 2020

This week, the FDA granted a Fast Track designation to the novel androgen receptor EPI-7386 as treatment of adult patients with metastatic castration-resistant prostate cancer who are resistant to standard of care treatment. A Breakthrough Therapy designation was also granted to magrolimab as treatment of patients with newly diagnosed myelodysplastic syndrome.

The Society of Hematologic Oncology (SOHO) hosted its eighth annual virtual meeting, in which attendance nearly doubled compared with previous years. The meeting focused on a theme of Molecular Classification and Precision Therapy with more than 150 presentations on a variety of hematologic malignancies.

Check out conference coverage from the ESMO Virtual Congress 2020.

These updates and others were trending this week:

Pennell Examines Targeted Therapies in EGFR-Mutated NSCLC​

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

HER2+ Breast Cancer Treatment Approaches Becomes More Individualized​

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, reviewed the 4 currently approved treatment options for patients with HER2-positive breast cancer and discussed how physicians could use the data to make treatment decisions in the adjuvant and neoadjuvant setting.

Ibrutinib and Venetoclax Under Investigation as First-Line Combo in MCL​

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.

Lymphoma Treatment Paradigm Refined Over Years, Expert Says on World Lymphoma Awareness Day​

In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.

Black Patients Experience Lower OS With CRC Liver Metastases Than Others​

Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival

Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD​

Uday R. Popat, MD, discusses the role of the JAK inhibitor ruxolitinib (Jakafi) as treatment of patients with graft-versus-host-disease.

Case-Based Peer Perspectives: A 73-Year-Old Man With Urothelial Carcinoma​

Neeraj Agarwal, MD, reviews the case of a 73-year-old man with unresectable, locally advanced urothelial carcinoma and discusses latest data and treatment approaches.

Special Feature: COVID-19 Update

More Analysis Is Needed of COVID-19, Cancer Interactions​

As COVID-19 alters current approaches to caring for patients with cancer, early emerging research data reinforce what practicing oncologists have been observing in their patients are at increased risk of mortality.